Time for treatment targets in rheumatoid arthritisBMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c4170 (Published 04 August 2010) Cite this as: BMJ 2010;341:c4170
- Paul Emery, Arthritis Research UK professor of rheumatology1
- For the Treat to Target UK Steering Group: Maya H Buch (University of Leeds), Andrew Östör (School of Clinical Medicine, University of Cambridge, Cambridge), Bruce Kirkham (Rheumatology Department, Guy’s Hospital, London), Peter Taylor (Department of Rheumatology, Charing Cross Hospital, London), Cristina Estrach (Aintree University Hospital, Liverpool), Tim Jenkinson (Rheumatology Sports and Exercise Medicine, Royal National Hospital for Rheumatic Diseases, Bath), Iain McInnes (University of Glasgow, Glasgow), Duncan Porter (Gartnavel General Hospital, Glasgow).
- 1University of Leeds, Leeds LS7 4SA
Binder and Ellis’s article on investigating symmetrical polyarthritis is pertinent to recent developments in managing rheumatoid arthritis.1 The recently published international “treat to target” recommendations for rheumatoid arthritis are an opportunity to examine the outcomes for UK patients against established and professional guidance.2 The goal should be remission or low disease activity only if …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial